FDFrançois Depasse

François Depasse

*This is an algorithmically generated author record based on publicly available information.

François Depasse has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach

    by Nikolaus B. Binder, François Depasse, Michael Spannagl, Jürgen Patzke, Stephan Schwers, Peter L. Turecek

    ADAMTS13, a crucial enzyme in hemostasis, that specifically cleaves von Willebrand factor (VWF), plays a pivotal role in the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura (TTP), a microcirculatory form of thrombotic microangiopathy (TMA). Its deficiency leads to the accumulation of ultra-large VWF multimers, causing microvascular thrombosis. Understanding and measuring ADAMTS13 activity are essential for diagnosis and management of TTP and other thrombotic diseases associated with ADAMTS13 deficiency. This review explores the evolution of ADAMTS13 assays from labor-intensive methods to rapid, automated platforms. It examines congenital and acquired ADAMTS13 deficiencies, highlighting diagnostic strategies and therapeutic interventions. A comprehensive literature search was conducted between September 2025 and June 2026 using PubMed and GoogleScholar, focusing on recent advancements and extending to foundational studies when necessary. The integration of rapid ADAMTS13 testing has the potential to improve clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. Despite progress, challenges remain in assay standardization, sensitivity, and interpretation. Future developments may include point-of-care technologies and conformation-sensitive assays to enhance relapse prediction and monitoring. Collaboration between clinicians and laboratories is crucial to optimize patient outcomes and advance the field of ADAMTS13 diagnostics.

  • Open Access

    Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches

    by François Depasse, Nikolaus B. Binder, Mariona Bono, Matthias Germer, Michael Heins, Martina Leplatoni, Jürgen Patzke, Stephan Schwers, Michael Spannagl, Peter L. Turecek

    Von Willebrandfactor (VWF) plays a crucial role in hemostasis: its interactions with endothelialmatrices, platelets, and factor VIII make it a key player in both primaryhemostasis and coagulation. Pathology associated with VWF spans mild to severebleeding manifestations in the case of inherited von Willebrand disease (VWD),the most common congenital bleeding disorder, or acquired von Willebrandsyndrome (AVWS). Conversely, VWF can be associated with thromboticmanifestations in situations related to inflammation, infection, or inheritedor acquired ADAMTS13 defects. This reviewarticle aims to provide guidance on the use and interpretation of clinicallaboratory assays available to measure VWF and other factors related to VWD.Different VWF tests can be used in different clinical settings for efficientdiagnosis and patient management. Assay limitations are also addressed. A myriad oflaboratory assays, from first line to esoteric assays, exist to enable adequatediagnosis of VWD and other diseases influenced by VWF. Clinical investigationsof VWF are complicated because VWF has multiple functions which variably dependon the patient's pathophysiological status. The right choice of assays istherefore critical to provide adequate diagnosis in due time and withreasonable analytical efforts.


  • Open Access

    Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases

    by Jürgen Patzke, Nikolaus B Binder, Mariona Bono, François Depasse, Matthias Germer, Michael Heins, Martina Leplatoni, Stephan Schwers, Michael Spannagl, Peter L Turecek

    Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF. As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods. This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.


  • Open Access

    Impact of Drugs Used in Intensive Care on Routine Coagulation Testing

    by Joffrey Feriel, Marjorie A. Goujon, Miki Desez, François Depasse

    Coagulation testing is commonly used in the intensive care unit (ICU) to monitor and manage the hemostatic balance, assess bleeding risk, and guide anticoagulant therapy. Routine tests used for this purpose include prothrombin time, activated partial thromboplastin time, fibrinogen, and anti-Xa assays. Some of the drugs commonly used in critically ill patients may influence coagulation assays by interacting in vitro with reagents or in vivo with coagulation pathways, thus altering the coagulation cascade and the fibrinolytic pathway. While the pharmacological effects of drugs on coagulation are usually documented, to our knowledge, no comprehensive review article has been published to date. In this review, we have conducted a critical analysis of the literature to define: (1) the impact of hydroxocobalamin, intravenous lipid emulsion, and propofol on chromogenic assays; (2) the impact of PEGylated compounds, emicizumab, recombinant activated factor VII, antibiotics, and sugammadex on chronometric assays; (3) the challenges associated with bridging anticoagulation in the ICU as well as the effect of N-acetylcystein, serotonin reuptake inhibitors, and tramadol on the hemostasis system. For each drug, we specify the routine coagulation assay that is impacted, whether this is linked to an in vitro interference or an in vivo effect, and the potential consequences on patient management.


  • Open Access

    Contact phase inhibitors: the future of anticoagulation?

    by Angèle Veyrat, François Depasse, Joffrey Feriel

    Thrombosis remains a major public health problem. Although traditional anticoagulants, vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) have been used with success over the last decades for prevention of venous thromboembolism (VTE) and stroke in non-valvular atrial fibrillation (AF), their use exposes the patient to an increased risk of bleeding. To overcome these limitations, new approaches are exploring contact phase inhibitors, specifically targeting factors XI, XIa, XII, and XIIa. Contact phase inhibitors including antisense oligonucleotides, monoclonal antibodies, small peptidomimetic molecules, aptamers and natural inhibitors seem promising in term of efficacy and safety. A common assay can be used to measure the anticoagulant activity of different drugs within a same pharmacological class (INR for VKAs) or even across different pharmacological classes (anti-Xa for all heparins and for direct factor Xa inhibitors). Because of the diversity of contact phase inhibitors, no specific common assay has been proposed so far. Activated partial thromboplastin time (aPTT) could play a role in the assessment of these new anticoagulants, but its relevance need to be confirmed. We aim at providing an overview of the pharmacological properties of contact phase inhibitors, the safety and efficacy outcomes from clinicals trials, as well as the possible coagulation assays relevant for patient follow-up.


  • Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples

    by Pierre‐Olivier Sevenet, Virginie Cucini, Tristan Hervé, François Depasse, Audrey Carlo, Geneviève Contant, Olivier Mathieu

    Introduction: Directs oral anticoagulants (DOACs) can interfere with coagulation assays, especially in thrombophilia workup. To avoid these interferences, a new device, DOAC Filter, allows the removal of DOACs from citrated plasma. This study aims to confirm that DOAC Filter efficiently removes DOACs and to ascertain that coagulation assays are not impacted by filtration.Methods: Directs oral anticoagulants Filter (Diagnostica Stago, France) is a filtration cartridge in which DOAC molecules are trapped by noncovalent binding, while plasma is filtered through a solid phase. Normal pool plasma (NPP) spiked with DOACs up to 300 ng/mL, with dabigatran etexilate (n = 27), rivaroxaban (n = 35), apixaban (n = 33), and edoxaban (n = 27) or 120 ng/mL for betrixaban (n = 4), and 18 plasma's samples from DOAC‐treated patients were used to assess efficacy. The potential impact of DOAC Filter on coagulation assays was evaluated with NPP and plasma's samples from positive and negative lupus anticoagulant (LA) patients.Results: Directs oral anticoagulants concentrations measured after filtration were below the limit of detection (LoD) of DOAC‐specific assays for all plasmas tested, except for one apixaban plasma sample, with postfiltration concentration slightly higher than anti‐Xa assay LoD (25.1 ng/mL). Coagulation assays results varied between −4 and +8% after filtration and between −6 and +8% for LA plasmas. Such limited variations are not expected to have any clinical impact.Conclusion: Directs oral anticoagulants Filter efficiently removes DOACs from plasma and achieves concentrations below DOAC‐specific assays LoD, except in the case of one apixaban sample. The integrity of plasma is respected, and the cartridge seems not to impact LA diagnosis.


  • Factor VII Deficiency: From Basics to Clinical Laboratory Diagnosis and Patient Management

    by Pierre-Olivier Sevenet, Daniel A. Kaczor, Francois Depasse

    Factor VII (FVII) deficiency is a rare inheritable bleeding disorder affecting 1/500 000 individuals. Clinical manifestations are heterogeneous, from asymptomatic to severe and potentially fatal bleeding. These clinical manifestations do not correlate well with FVII plasma levels. For this reason, FVII-deficient patient management during surgery or for long-term prophylaxis remains challenging. Laboratory testing for FVII activity is, however, the first-line method for FVII deficiency diagnosis and is helpful for managing patients in combination with clinical history. Additional testing consists of FVII immunoassay and genetic testing. Genetic abnormalities on the FVII gene are heterogeneous and can translate into quantitative or qualitative defects. Some of the latter can react differently with different thromboplastins; this can be misleading for the laboratory as no consensus exists at present on an FVII deficiency diagnosis methodology. Indeed, no single test is able to predict accurately the bleeding risk. This review provides a broad picture of inherited and acquired FVII deficiency with a particular focus on laboratory diagnosis.